S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive
mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus
gefitinib versus gefitinib monotherapy